

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

1 **Bi-allelic loss-of-function variants in *PPFIBP1* cause a**
2 **neurodevelopmental disorder with microcephaly, epilepsy and**
3 **periventricular calcifications**

4
5 Erik Rosenhahn,^{1,33} Thomas J. O'Brien,^{2,3,33} Maha S. Zaki,⁴ Ina Sorge,⁵ Dagmar Wiczorek,⁶
6 Kevin Rostasy,⁷ Antonio Vitobello,⁸ Sophie Nambot,⁹ Fowzan S. Alkuraya,^{10,11} Mais O.
7 Hashem,¹⁰ Amal Alhashem,^{11,12} Brahim Tabarki,¹² Abdullah S. Alamri,¹³ Ayat H. Al Safar,¹³
8 Dalal K. Bubshait,¹³ Nada F. Alahmady,¹⁴ Joseph G. Gleeson,^{15,16} Mohamed S. Abdel-Hamid,
9 ¹⁷ Nicole Lesko,^{18,19} Sofia Ygberg,^{18,19,20} Sandrina P. Correia,^{19,21} Anna Wredenberg,^{18,19}
10 Shahryar Alavi,^{22,23} Seyed M. Seyedhassani,²⁴ Mahya Ebrahimi Nasab,²⁴ Haytham Hussien,²⁵
11 Tarek Omar,²⁵ Ines Harzallah,²⁶ Renaud Touraine,²⁶ Homa Tajsharghi,²⁷ Heba Morsy,²⁸
12 Henry Houlden,²⁸ Mohammad Shahrooei,^{29,30} Maryam Ghavideldarestani,²⁹ Johannes R.
13 Lemke,^{1,31} Heinrich Sticht,³² Rami Abou Jamra,¹ Andre E. X. Brown,^{2,3,34,*} Reza
14 Maroofian,^{28,34} Konrad Platzer^{1,34,*}

15

16 **Affiliations:**

- 17 1. Institute of Human Genetics, University of Leipzig Medical Center, 04103 Leipzig,
18 Germany
19 2. MRC London Institute of Medical Sciences, London W12 0NN, UK
20 3. Faculty of Medicine, Institute of Clinical Sciences, Imperial College London, London
21 SW7 2AZ, UK
22 4. Clinical Genetics Department, Human Genetics and Genome Research Institute, National
23 Research Centre, Cairo 12622, Egypt
24 5. Department of Pediatric Radiology, University Hospital Leipzig, 04103 Leipzig, Germany

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

- 25 6. Institute of Human Genetics, Medical Faculty and University Hospital Düsseldorf,
26 Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany
- 27 7. Department of Pediatric Neurology, Children's and Adolescents' Hospital Datteln,
28 Witten/Herdecke University, 58448 Witten, Germany
- 29 8. UF6254 Innovation en Diagnostic Genomique des Maladies Rares, CHU Dijon
30 Bourgogne, FHU translad, Génétique des Anomalies du Développement, INSERM UMR
31 1231, Université de Bourgogne-Franche Comté, 21070 Dijon, France
- 32 9. Centre de Génétique et Centre de référence des Maladies rare, Anomalies du
33 Développement et Syndromes Malformatifs, Hôpital d'Enfants, Centre Hospitalier
34 Universitaire de Dijon, 21079 Dijon, France
- 35 10. Department of Translational Genomics, Center for Genomic Medicine, King Faisal
36 Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia
- 37 11. Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University,
38 Riyadh Riyadh 11211, Saudi Arabia
- 39 12. Department of Pediatrics, Prince Sultan Military Medical City, Riyadh 12233, Saudi
40 Arabia
- 41 13. Department of Pediatrics, Imam Abdulrahman bin Faisal University, Dammam 34212,
42 Saudi Arabia
- 43 14. Biology Department, Imam Abdulrahman bin Faisal University, Dammam 34212, Saudi
44 Arabia
- 45 15. Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093,
46 USA
- 47 16. Rady Children's Institute for Genomic Medicine, San Diego, La Jolla, CA 92093, USA
- 48 17. Medical Molecular Genetics Department, Human Genetics and Genome Research
49 Institute, National Research Centre, Cairo 12622, Egypt

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

- 50 18. Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77
51 Stockholm, Sweden
- 52 19. Centre for Inherited Metabolic Diseases, Karolinska University Hospital, 171 76
53 Stockholm, Sweden
- 54 20. Neuropediatric Unit, Department of Women's and Children's Health, Karolinska
55 University Hospital, 171 77 Stockholm, Sweden
- 56 21. Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm,
57 Sweden
- 58 22. Department of Cell and Molecular Biology and Microbiology, Faculty of Biological
59 Science and Technology, University of Isfahan, Isfahan, Iran
- 60 23. Palindrome, Isfahan, Iran
- 61 24. Dr. Seyedhassani Medical Genetic Center, Yazd, Iran
- 62 25. Alexandria University Children's Hospital, Faculty of Medicine, Alexandria University,
63 Alexandria 21526, Egypt
- 64 26. Clinical, Chromosomal and Molecular Genetics Department, University Hospital Center,
65 42270 Saint-Étienne, France
- 66 27. School of Health Sciences, Translational Medicine, University of Skövde, 541 28 Skövde,
67 Sweden
- 68 28. UCL Queen Square Institute of Neurology, University College London, London WC1N
69 3BG, United Kingdom
- 70 29. Specialized Immunology Laboratory of Dr. Shahrooei, Sina Medical Complex, Ahvaz,
71 Iran
- 72 30. Department of Microbiology and Immunology, Clinical and Diagnostic Immunology, KU
73 Leuven, 3000 Leuven, Belgium
- 74 31. Center for Rare Diseases, University of Leipzig Medical Center, 04103 Leipzig, Germany

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

75 32. Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054

76 Erlangen, Germany

77

78 33. These authors contributed equally.

79

80 34. These authors contributed equally.

81

82 * Correspondence: konrad.platzer@medizin.uni-leipzig.de; andre.brown@lms.mrc.ac.uk

83

84 **Abstract**

85 *PPFIBP1* encodes for the liprin- β 1 protein which has been shown to play a role in neuronal
86 outgrowth and synapse formation in *Drosophila melanogaster*. By exome sequencing, we
87 detected nine ultra-rare homozygous loss-of-function variants in 14 individuals from 10
88 unrelated families. The individuals presented with moderate to profound developmental delay,
89 often refractory early-onset epilepsy and progressive microcephaly. Further common clinical
90 findings included muscular hypertonia, spasticity, failure to thrive and short stature, feeding
91 difficulties, impaired hearing and vision, and congenital heart defects. Neuroimaging revealed
92 abnormalities of brain morphology with leukoencephalopathy, cortical abnormalities, and
93 intracranial periventricular calcifications as major features. In a fetus with intracranial
94 calcifications, we identified a rare homozygous missense variant that by structural analysis
95 was predicted to disturb the topology of the SAM-domain region that is essential for protein-
96 protein interaction. For further insight in the effects of *PPFIBP1* loss-of-function, we
97 performed automated behavioural phenotyping of a *Caenorhabditis elegans PPFIBP1/hlb-1*
98 knockout model which revealed defects in spontaneous and light-induced behaviour and
99 confirmed resistance to the acetylcholinesterase inhibitor aldicarb suggesting a defect in the
100 neuronal presynaptic zone. In conclusion, we present bi-allelic loss-of-function variants in
101 *PPFIBP1* as a novel cause of an autosomal recessive neurodevelopmental disorder.

102

103 **Introduction**

104 *PPFIBP1* (GenBank: NM_003622.4; MIM: 603141) encodes for the PPFIA binding protein
105 1, also known as liprin- β 1. Liprin- β 1 belongs to the liprin-protein family whose members are
106 characterised by a highly conserved N-terminal coiled coil region and three adjacent C-
107 terminal sterile alpha motifs (SAM domains) that form multiple protein binding surfaces and
108 allow for protein-protein interaction.¹⁻³ In mammals, the liprin family comprises four liprin- α
109 proteins (liprin- α 1-4) and two liprin- β proteins (liprin- β 1 and - β 2). Liprin- β 1 has the ability to
110 homodimerize and to heterodimerize with the homologous α -liprins.¹ In addition, liprin- β 1
111 and liprin- α 1 co-localize to the cell membrane and to the periphery of focal adhesions in
112 fibroblast cell cultures (COS cells).^{1,4} Liprin- α proteins are major scaffold proteins involved
113 in synapse formation, synaptic signaling and axonal transport processes via the assembly of
114 large protein complexes.^{5,6} Although yet to be confirmed, it has been suggested, that liprin- β 1
115 could play a role in the regulation of liprin- α mediated protein assemblies.^{1,6,7} In line with this
116 is the observation that liprin- β 1 forms a ternary complex with liprin- α 2 and CASK,³ a
117 presynaptic scaffolding protein essential for neurodevelopment.^{8,9} A previous knock-out
118 model of the *PPFIBP1* homolog *h1b-1* in *C. elegans* showed abnormal locomotion behavior.
119 Furthermore, abnormal and decreased distribution of *snb-1*, an ortholog of human VAMP-
120 family proteins involved in presynaptic vesicle release, increased presynaptic zone size and
121 resistance to the acetylcholinesterase inhibitor aldicarb indicated a role of *h1b-1* in the
122 regulation of presynaptic function.¹⁰ Pointing towards a role in neurodevelopment, null-allele
123 mutants of the liprin- β 1 orthologue liprin- β resulted in altered axon outgrowth and synapse
124 formation of R7 photoreceptors and also reduced larval neuromuscular junction (NMJ) size in
125 *D. melanogaster*.⁷ Indeed, *PPFIBP1* has been proposed as a candidate gene for congenital
126 microcephaly based on a single family although this link remains tentative and requires
127 independent confirmation.¹⁰

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

128 Here we describe a cohort of 14 individuals with a neurodevelopmental disorder from ten
129 unrelated families harboring homozygous loss-of-function (LoF) variants and a fetus with a
130 missense variant in *PPFIBP1*.

131

132 **Subjects and methods**

133 **Patient recruitment and consent**

134 The study was approved by the ethics committee of the University of Leipzig (402/16-ek).
135 Written informed consent for molecular testing and permission for publication of the data was
136 obtained from all individuals and/or their legal representatives by the referring physicians
137 according to the guidelines of the ethics committees and institutional review boards of the
138 respective institute.

139 All individuals were ascertained in the context of local diagnostic protocols followed by
140 research evaluation of the sequencing data. The compilation of the cohort was supported by
141 international collaboration and online matchmaking via GeneMatcher¹¹ in the case of family
142 2, 4, 5, 6, 7, 8, 9, 10 and 11. Family 3 was recently published as part of a larger cohort of
143 individuals with congenital microcephaly.¹² In the context of our study we describe the
144 phenotype in detail. Phenotypic and genotypic information were obtained from the referring
145 collaborators using a standardized questionnaire.

146

147 **Exome sequencing**

148 Trio exome sequencing (ES) and trio genome sequencing were performed for the affected
149 individuals and the parents in the families 1, 2, 5 and 11 and in family 7, respectively.

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

150 Singleton exome sequencing was performed for all affected individuals of the families 3, 4, 6,
151 8, 9 and 10 (see Supplemental methods for further details).

152

153 **Variant prioritization**

154 We first analysed single nucleotide variants annotated in local and public mutation databases,
155 as well as rare (MAF < 1%) potentially protein-damaging variants in known disease-
156 associated genes (e.g. by using in silico panels like MorbidGenes¹³). Variants were prioritised
157 based on the mode of inheritance, impact on the gene product, minor allele frequency and *in*
158 *silico* predicted pathogenicity. Since no pathogenic or likely pathogenic variants in known
159 disease genes could be found and the families gave consent for further research, we then
160 evaluated the sequencing data in a research setting aiming to identify potentially causative
161 variants in novel candidate genes. For this purpose, variants in potential candidate genes were
162 prioritised according to the parameters described above and by considering further data such
163 as mutational constraint parameters from gnomAD¹⁴ or expression patterns in GTEx.¹⁵

164 All variants in *PPFIBP1* described here were aligned to the human reference genome version
165 GRCh38 (hg38) and to the transcript NM_003622.4 (Ensembl: ENST00000228425.11)
166 representing the transcript with the highest expression across all tissues¹⁵ and the MANE
167 Select v0.95 default transcript. The pathogenicity of all described variants was classified
168 according to the guidelines of the American College of Medical Genetics (ACMG)¹⁶ (Table
169 S1).

170

171 **Structural analysis**

172 Structural analysis of the p.(Gly726Val) variant was performed based on the crystal structure
173 of murine PPFIBP1 (PDB: 3TAD³), which exhibits 97% sequence identity to its human

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

174 ortholog in the region of the SAM domains. The exchange was modeled with SwissModel¹⁷
175 and RasMol¹⁸ was used for structure analysis and visualization. Structural analysis for the
176 other variants was not necessary as all are LoF variants and predicted to lead to a loss of
177 protein.

178

179 **Mutant *C. elegans* generation**

180 The knockout worm model was designed and made by SunyBiotech (Fuzhou, Fujian, China)
181 in their reference N2 background. CRISPR guide RNA was designed to target a large deletion
182 (17118 bp) starting close to the start codon and excising all exons from the gene. Deletions
183 were confirmed by PCR.

184

185 **Worm preparation**

186 All strains were cultured on Nematode Growth Medium at 20°C and fed with *E. coli* (OP50)
187 following standard procedure.¹⁹ Synchronised populations of young adult worms for imaging
188 were cultured by bleaching unsynchronised gravid adults, and allowing L1 diapause progeny
189 to develop for two and a half days at 20°C.²⁰ On the day of imaging, young adults were
190 washed in M9²¹, transferred to the imaging plates (3 worms per well) using a COPAS 500
191 Flow Pilot²², and returned to a 20°C incubator for 3.5 hours. Plates were then transferred onto
192 the multi-camera tracker for another 30 minutes to habituate prior to imaging²³. For drug
193 experiments, imaging plates were dosed with the compound at the desired concentration one
194 day prior to imaging. Worms were then dispensed and tracked as described above, except for
195 the 1h exposure time where worms were returned to a 20°C incubator for 30 minutes and then
196 transferred to the tracker for 30 minutes prior to imaging²⁴.

197

Rosenhahn *et al.*, *PPFIBPI*-related neurodevelopmental disorder

198 **Image acquisition, processing and feature extraction**

199 Videos were acquired and processed following methods previously described in detail²⁵.
200 Briefly, videos were acquired in a room with a nominal temperature of 20°C at 25 frames per
201 second and a resolution of 12.4 $\mu\text{m px}^{-1}$. Three videos were taken sequentially: a 5-minute
202 pre-stimulus video, a 6-minute blue light recording with three 10-second blue light pulses
203 starting at 60, 160 and 260 seconds, and a 5-minute post-stimulus recording.

204 Videos were segmented and tracked using Tierpsy Tracker.²⁴ After segmentation and
205 skeletonisation, a manual threshold was applied to filter skeletonised objects, likely to be non-
206 worms from feature extraction, that did not meet the following criteria: 200 – 2000 μM
207 length, 20 – 500 μM width. Tierpsy Tracker’s viewer was also used to mark wells with visible
208 contamination, agar damage, or excess liquid as “bad”, and exclude these wells from
209 downstream analysis.

210 Following tracking, we extracted a previously-defined set of 3076 behavioural features for
211 each well in each of the three videos (pre-stimulus, blue light and post-stimulus).²⁶ The
212 extraction of behavioural features was performed on a per-track basis and are then averaged
213 across tracks to produce a single feature vector for each well. Statistically significant
214 differences in the pre-stimulus, post-stimulus and blue-light behavioural feature sets extracted
215 from the loss-of-function mutant compared to the N2 reference strain were calculated using
216 block permutation t-tests (code available on GitHub, see web resources). Python (version
217 3.8.5) was used to perform the analysis, using $n = 10^6$ permutations that were randomly
218 shuffled within, but not between, the independent days of image acquisition in order to
219 control for day-to-day variation in the experiments. The p-values were then corrected for
220 multiple comparisons using the Benjamini-Hochberg procedure²⁷ to control the false
221 discovery rate at 5%.

222

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

223 **Pharyngeal pumping assay**

224 Pharyngeal pumps per minute (ppm) of *C. elegans* strains were determined by counting
225 grinder movements over a 15 second period by eye using a stereomicroscope²⁸, n = 120
226 worms per strain. Grinder movements of a single worm were counted three times and the
227 results recorded as an average of these values. Statistical differences in ppm between N2
228 reference strain and *h1b-1(syb4896)* were calculated using block permutation t-tests, using n =
229 10³ permutations.

230

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

231 **Results**

232 **Clinical description**

233 All individuals share a core phenotype of global developmental delay / intellectual disability
234 (GDD/ID) and epilepsy. 13 were affected by profound or severe GDD/ID (13/14). They had
235 not acquired speech (13/14) and showed impaired motor development (13/14). Most of them
236 never achieved gross motor milestones such as sitting and walking except for individual 6-1
237 who was able to sit independently at the age of (removed due to medRxivpolicy) and
238 individual 7 who could stand and walk. Individual 1 presented with moderate ID, developed
239 expressive language skills and had a normal motor development. All individuals were affected
240 by epilepsy: most commonly with focal seizures (9/14) including cases of impaired awareness
241 (1/14) and focal to bilateral tonic-clonic (1/14) seizures. Furthermore, generalized onset
242 seizures occurred in six of the individuals (6/14). Epileptic spasms were described in half of
243 the cohort (7/14). Other reported seizure types included tonic (3/14) and myoclonic seizures
244 (6/14). The median age of seizure onset was at two months with a range from the first day of
245 life up to four years. Many individuals were initially affected by daily seizures (9/14). All
246 individuals have been treated with multiple antiepileptic drugs (AED). However, seizures
247 were refractory in six of the individuals (6/14). Seizures could be reasonably controlled in
248 individual 1, individual 5-1, individual 6-1 and individual 8 with a therapy of Lamotrigine
249 (LTG) and Oxcarbazepine (OXC), a therapy with Valproic acid (VPA), Clonazepam (CZP),
250 Carbamazepine (CBZ), Levetiracetam (LEV) and LTG, a therapy with VPA, LEV and CZP
251 and a therapy with Topiramate, VPA and LEV, respectively. The seizures completely ceased
252 in individual 2, individual 7 and individual 10 under therapy with LEV and CZP, with VPA
253 and with VPA and Diazepam, respectively. Individual 9 was reported to have had a seizure-
254 free period. Electroencephalography (EEG) was performed in 12 individuals (Table S4). EEG
255 findings included focal (3/12) or multifocal (5/12) interictal epileptiform discharges. In one

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

256 individual, bilateral paroxysmal discharges were observed. Hypsarrhythmia was recorded in
257 four individuals (4/12) who were also affected by epileptic spasms and thus met the criteria
258 for West syndrome. In one of these cases, the phenotype progressed to Lennox-Gastaut
259 syndrome later. All but individual 8 were affected by microcephaly, defined here by an
260 occipitofrontal circumference (OFC) ≤ -2 standard deviations (SD) (range: $\ll -3$ SD to -1.78
261 SD) at last assessment). The majority showed primary (9/14) and/or progressive (10/14)
262 microcephaly. Secondary microcephaly developed in individual 1, individual 6-1 who had
263 low OFC (-1.94 SD) already at birth, and individual 7. Individual 8 showed borderline low
264 normal head circumference at the last assessment. Other common neurological findings
265 comprise muscular hypertonia (10/14) up to spastic tetraplegia (8/14), but also muscular
266 hypotonia (3/14), dystonic movements (2/14) and nystagmus (3/14).

267 Eight individuals were born small for gestational age (birthweight $\leq 10^{\text{th}}$ percentile; 8/14).
268 Failure to thrive leading to decreased body weight (≤ -2 SD) was seen in seven individuals
269 (7/14) and short stature (height ≤ -2 SD) manifested in six (6/14). Some of the individuals
270 exhibited feeding difficulties (6/14) and deglutition disorders were described in three of them.

271 Other repeatedly described symptoms include impaired hearing (4/14), ophthalmologic
272 abnormalities (6/14), undescended testes (3/9) and congenital heart defects (6/14). The latter
273 comprise patent ductus arteriosus (5/14, PDA), atrial septal defects (3/14, ASD), ventricular
274 septal defects (2/14, VSD), a dilated left ventricle (1/14) and a coronary fistula (1/14) with
275 mitral regurgitation and cardiomegaly. There were no overarching dysmorphic facial features
276 in the affected individuals. (For an overview of the phenotypic spectrum see **Table 1** and
277 **Figure 1A**. For further details on the phenotype of each individual see case reports in
278 supplemental data and Table S4).

279

280 **Neuroimaging**

Rosenhahn *et al.*, *PPFIBPI*-related neurodevelopmental disorder

281 Neuroimaging revealed abnormalities of brain morphology in all twelve individuals that
282 underwent MRI except for individual 1 who had a normal MRI at the age of (removed due to
283 medRxivpolicy). Ten individuals presented signs of leukoencephalopathy (10/12) mainly in a
284 periventricular localisation (8/12) (**Figure 1C**). Four of the individuals showed paucity of the
285 white matter (4/12). For each of the individuals 3-2 and 4, MRI data from two different time
286 points was available, which suggested a progression of the periventricular hyperintensities
287 and loss of white matter, respectively. Five individuals had abnormalities of the cortex
288 morphology (5/12) including pachygyria and thickening of the cortex in three individuals
289 (3/12) (**Figure 1C**) with one of them showing severe periventricular grey matter heterotopia
290 (1/12; **Figure 1C**: Individual 8). Ventriculomegaly of variable degree (8/12) was a common
291 finding. Other notable findings included a thin corpus callosum (6/12), cerebellar vermian
292 hypoplasia (2/12) and a Blake's pouch cyst in individual 2. Head CT scan, performed in eight
293 individuals, revealed bilateral intracranial calcifications (ICC) in all of them (8/8).
294 Calcifications mostly appeared in a scattered pattern with periventricular localisation (8/8) but
295 also the basal ganglia (4/8), centra semiovale (2/8) and internal capsule (1/8) were affected
296 (**Figure 1C**). Furthermore, CT scan also showed ventriculomegaly in individual 5-2 who did
297 not have MRI.

298

299 **Fetal phenotype**

300 The fetus (individual 11) showed severe intrauterine growth retardation and microcephaly
301 during pregnancy and the pregnancy was terminated in the 25th gestational week. Autopsy
302 confirmed length and weight below -2 SD and an occipitofrontal circumference below -4 SD.
303 An x-ray babygram showed ICCs (**Figure 1B**) and in the histopathological examination of the
304 brain, predominant macrocalcification and rare necrotic foci in the process of calcification in

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

305 the germinative and periventricular areas around the 3rd ventricle and occipital horns were
306 described, as well as cerebral edema with spongiosis and glial response.

307

308 **Genetic results**

309 ES revealed homozygous LoF variants in *PPFIBP1* (NM_003622.4) in all affected
310 individuals. In the affected individuals of the families 2, 3, 4, 5, 6, 7, 8, 9 and 10, we detected
311 eight different homozygous protein-truncating variants. These comprise five nonsense
312 variants and three frameshift variants of which one was recurrent in all affected individuals
313 from the two unrelated families 3 and 4 (all variants are displayed in **Table 1**). Since all of
314 these variants lead to premature termination codons >50 nucleotides upstream of the last
315 exon-exon splice junction considering the transcripts with the highest expression overall and
316 in brain tissues in specific (NM_003622 and NM_001198915.2),^{14,15} they are predicted to
317 undergo nonsense mediated mRNA decay (NMD).²⁹ Only for the variant c.403C>T,
318 p.(Arg135*), NMD can only be predicted with respect to transcript NM_003622.4, as the
319 variant lies in the 5' untranslated region (UTR) of the transcript NM_001198915.2. All LoF
320 variants mentioned above can be classified as pathogenic according to the guidelines of the
321 ACMG (Table S1).

322 In family 1, a homozygous splice-site variant c.1146+1G>A, p.? affecting the consensus 5'-
323 splice site of exon 13 was identified. Multiple *in silico* tools consistently predict a loss of the
324 splice site (Table S2). This could lead to out-of-frame exon skipping or to intron retention.^{30,31}
325 Thus, the mRNA resulting from this allele is likely to encode a truncated protein as well.

326 Furthermore, in a fetus, a homozygous missense variant c.2177G>T, p.(Gly726Val) was
327 identified. The missense variant lies in the second SAM-domain (**Figure 2A**) and affects a
328 highly conserved amino acid considering nine species up to the Opossum. Multiple *in silico*

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

329 tools consistently predicted a damaging effect of the variant (Table S3). Structural analysis
330 showed that Gly726 is located in a tight turn of the second SAM-domain of *PPFIBP1* (**Figure**
331 **2B**). At this position, a valine can only be accommodated in a strained backbone
332 conformation resulting in domain destabilization. In addition, the longer valine sidechain
333 causes steric problems with Asn803 located in the third SAM domain (**Figure 1B**), which are
334 predicted to disrupt the domain interface.

335 All of the identified variants are very rare in the general population, represented by the
336 gnomAD database.¹⁴ The variants detected in the families 1, 2, 3, 4, 6, 8, 9, 10 and in the fetus
337 are absent from gnomAD. Five alleles are reported for the variant identified in family 5 (MAF
338 of 0.0000199) and 7 alleles are reported for the variant identified in family 7 (MAF of
339 0.00002828), all in heterozygous state in each case. The parents were confirmed as
340 heterozygous carriers in the families 1, 2, 4, 5, 6, 7, 8 and 11.

341

342 **Modelling loss of *PPFIBP1* in *C. elegans***

343 Worm models are useful for modelling the underlying mechanistic causes of genetic
344 disorders. CRISPR-Cas9 was used to knock out the *C. elegans PPFIBP1* homolog, *h1b-1*,¹⁰
345 and generate a putative LoF mutant, *h1b-1(syb4896)*. Automated quantitative phenotyping of
346 the disease model mutant was then used to identify differences compared to the wild-type
347 strain N2 across a range of behavioural dimensions.²⁶

348 The *h1b-1(syb4896)* mutant showed a significant increase in body curvature (**Figure 3A**). In
349 existing *C. elegans* models of epilepsy “head bobbing” is a phenotype associated with
350 convulsions and the onset of seizures.³² We saw no statistically significant difference in the
351 head movement of *h1b-1(syb4896)* compared to N2 during baseline (pre-stimulus) tracking
352 (**Figure 3B**). However, upon stimulation with pulses of blue light, a significant increase in the

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

353 acceleration of the head tip (indicative of increased head movement) was observed for mutant
354 strains (**Figure 3C**), highlighting some overlap in the behavioural phenotype of *hllb-*
355 *I(syb4896)* and other pre-existing worm models of epilepsy. Thus, this finding indirectly
356 suggests some elements of a mild epileptic phenotype may be present in *hllb-I(syb4896)*.

357 There is little difference in the baseline locomotion of *hllb-I(syb4896)* and N2 (**Figure 3E**).
358 However, *hllb-I(syb4896)* displays a short-lived photophobic escape response when pulsed
359 with blue light, as demonstrated by the LoF mutant returning to a paused state faster upon the
360 cessation of the aversive stimulus (**Figure 3F-G**). We also note that there is an attenuated
361 change in posture of *hllb-I(syb4896)* during blue light tracking (**Figure 3H**).

362 A previous study into the function of *hllb-I* in *C. elegans* identified a defect in pharyngeal
363 pumping rate,¹⁰ that we also confirm for *hllb-I(syb4896)* (**Figure 3D**), and enlarged pre- and
364 post-synaptic sites. Given the role of aberrant synaptic transmission events in the onset of
365 epileptic seizures and the hypothesis that liprin-β1 acts as a core scaffold to mediate protein
366 assembly in the presynaptic zone,³ we investigated if our quantitative phenotyping approach
367 could detect a defect in the synaptic transmission apparatus of *hllb-I(syb4896)*.

368 Aldicarb is an acetylcholinesterase inhibitor that induces paralysis of the body-wall muscles
369 in *C. elegans* due to an accumulation of acetylcholine (ACh) and the subsequent
370 overstimulation of acetylcholine receptors. Increased resistance to aldicarb occurs if mutations
371 give rise to defects in presynaptic function, as ACh accumulates in the neuromuscular
372 junction at a slower rate.³³ Indeed, *hllb-I(syb4896)* showed a significant dose-dependent
373 decrease in the fraction of paused worms that were exposed to 1 – 10 μM aldicarb for 1h
374 compared to N2 (**Figure 4A**), demonstrating increased aldicarb resistance. Levamisole is a
375 paralysis-inducing ACh receptor agonist. Resistance to levamisole has been shown to persist
376 in worms if mutations affect the postsynaptic site, whereas sensitivity to levamisole persists if
377 mutations only affect the presynaptic site.³⁴ In contrast to previous *hllb-I* studies¹⁰, we do not

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

378 observe any resistance to levamisole in *hlb-1(syb4896)* worms. If anything, there is an
379 increased sensitivity observed at 10 μ M levamisole for 4h (**Figure 4B**).

380 These findings provide evidence that a defect arises in the presynaptic, but not postsynaptic,
381 apparatus of *C. elegans* due to *hlb-1* LoF. Coupled with existing evidence that liprins are
382 involved in the assembly of presynaptic active zones across species,^{3,7} this points towards a
383 conserved biological role of *hlb-1* and its homologs in regulating the formation of NMJs and
384 supports presynaptic defects as a cause the pathologies arising from mutations in *PPFIBP1*.

385

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

386 Discussion

387 Here we describe 14 individuals from ten unrelated families with a core phenotype of
388 moderate to profound developmental delay, progressive microcephaly, epilepsy and
389 periventricular calcifications. In all 14 individuals, ES revealed rare homozygous LoF variants
390 in *PPFIBP1*. In addition, we describe a fetus with severe growth restriction, microcephaly and
391 intracranial calcifications with a homozygous missense variant that is *in silico* and structurally
392 predicted to be disrupting.

393 Consistent with the proposed autosomal recessive inheritance, LoF variants in *PPFIBP1* in
394 general are not common with an observed/expected ratio (*o/e*) of 0.57 (90% confidence
395 interval= 0.43-0.75). In addition, there were no homozygous LoF variants observed in
396 gnomAD. Since all described variants are ultra-rare, (MAF < 0.01) it is highly unlikely to
397 assemble a cohort with this level of phenotypical overlap and homozygous LoF variants in
398 *PPFIBP1* by coincidence which further strengthens disease causality.

399 The 13 individuals harbouring homozygous frameshift or nonsense variants exhibit a
400 consistent phenotype in terms of the severity of the developmental delay, epilepsy and
401 frequently found neuroimaging features. Only individual 7 presented a milder disease course
402 compared to the other individuals with truncating variants as she had secondary microcephaly,
403 was able to stand and walk, albeit showing impaired motor development, and showed less
404 prominent neuroimaging features. The nonsense variant c.403C>T, p.(Arg135*) found in
405 individual 7 lies in the 6th exon thus being the most upstream variant in this cohort. It is
406 predicted to cause NMD considering the transcript NM_003622.4 which shows the highest
407 overall expression and thereby likely has the highest biological relevance. Nevertheless, it
408 cannot be ruled out that a shorter transcript like NM_001198915.2 with its start codon lying
409 57 base pairs downstream of this variant could compensate for the loss of the main transcript

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

410 to some extent. NM_001198915.2 has the second highest mean expression across all tissues
411 and particularly shows expression levels that are comparable to those of NM_003622.4 in
412 some areas of the brain.¹⁵

413 Individual 1 with the homozygous splice-site variant has a milder phenotype compared to the
414 other individuals with nonsense or frameshift variants, although he shares the core clinical
415 signs. This could be due to an incomplete splice defect, either leading to the expression of a
416 fraction of normal protein or to an altered protein not completely impaired in function or
417 stability. Canonical splice site variants as observed in individual 1 can have a variety of
418 effects on pre-mRNA splicing such as exon skipping which is the most common mechanism
419 in variants disrupting consensus 5'-donor splice sites³⁰ or intron retention, both of which
420 would result in a frameshift in this case. However, a loss of the splice site could also enable
421 the activation of a cryptic splice site with consequent inclusion of an intron fragment or the
422 removal of an exon fragment, both of which can lead to a variety of aberrant transcripts.

423 The pathogenicity of the missense variant identified in the fetus is not as clear as that of the
424 LoF variants. However, the striking similarity of the intracranial calcifications, the growth
425 restriction and the severe microcephaly represent a significant phenotypic overlap with the
426 rest of the cohort, suggesting this variant to be causative. Potential pathogenicity of the
427 variant is further supported by its absence from the general population, multiple supported by
428 *in silico* predictions and its expected effects on the SAM-domains from structural analysis.
429 SAM-domains are a family of protein interaction modules present in a wide variety of
430 proteins.³⁵ The Gly726Val exchange is located in the second SAM-domain of PPFIBP1
431 destabilizing both the second SAM-domain and the interaction between the second and third
432 SAM domain. Therefore, this variant is expected to severely disturb the topology of the SAM-
433 domain region and its function in protein-protein interactions. Given the hypothesis that

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

434 liprin- β 1 acts as a core scaffold to mediate protein assembly in the presynaptic zone,³ the
435 ability to precisely interact with other proteins would appear to be critical for protein function.

436 ICCs located in the periventricular area but also affecting the basal ganglia and the internal
437 capsule appear to be a highly characteristic sign in this cohort. Pathologic ICCs have
438 heterogeneous aetiologies such as neoplastic, infectious, vascular, metabolic and genetic
439 conditions.³⁶ Congenital infections with pathogens of the TORCH-spectrum, and congenital
440 cytomegalovirus (CMV) infections in particular, account for a significant amount of
441 congenital and paediatric ICCs that are associated with brain malformations and impaired
442 neurodevelopment.³⁷ However, genetic disorders such as interferonopathies represent
443 important differential diagnoses for congenital ICC and some conditions significantly overlap
444 with the symptomatic spectrum of congenital TORCH-infections.^{38–40} It is assumed that the
445 genetic aetiologies of unsolved ICCs have not been fully discovered yet.^{37,41} Individual 4 was
446 admitted to the neonatal intensive care unit for one month after birth, as his clinical
447 presentation was indicative of a congenital CMV infection (see case reports in Supplemental
448 data for further details). However, an active CMV infection could not be confirmed in
449 standard laboratory diagnostics. In both affected siblings of family 5 and in individual 6-2, a
450 screening for infections of the TORCH spectrum was performed with negative results and
451 also the fetus was tested negative for CMV.

452 The biological function of liprin- β 1 and its molecular mechanisms are still largely unstudied.
453 However, recent studies point towards a role in neurodevelopment that echo the findings of a
454 neurodevelopmental disorder in the cohort described here. Liprin- β 1 has been identified as a
455 binding partner of liprin- α proteins. The role of liprin- α proteins or their orthologues, in
456 synapse formation and synaptic transmission has been demonstrated in previous animal model
457 studies.^{7,42–44} Liprin- α proteins function as major scaffold proteins at the presynaptic active
458 zone and at the postsynaptic density and also play a role in intracellular transport, cell motility

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

459 and protein assembly.^{3,5,6,45–47} Wei *et al.* found that liprin- α 2 forms a ternary complex
460 simultaneously binding liprin- β 1 and CASK, another presynaptic scaffold protein, supporting
461 the hypothesis that liprin- β 1 could act as a core scaffold and mediate large protein assemblies
462 in the presynaptic active zone.³ Interestingly, pathogenic variants in *CASK* (MIM: 300172)
463 are associated with X-linked neurodevelopmental disorders.⁴⁸ Pathogenic variants in *CASK*
464 cause X-linked neurodevelopmental disorders with varying phenotypes depending on variant
465 type and inheritance. In particular, heterozygous and hemizygous LoF variants in *CASK* lead
466 to Microcephaly with pontine and cerebellar hypoplasia (MICPCH [MIM: 300749]). The
467 phenotypic spectrum comprises moderate to profound ID, progressive microcephaly, impaired
468 hearing, ophthalmologic anomalies, muscular hypo- or hypertonia and spasticity, as well as
469 seizures and partly epileptic encephalopathy in males.⁴⁸ Since the phenotype is overlapping
470 with the clinical signs found in this cohort, it seems possible that *PPFIBP1* and *CASK* are
471 involved in similar biological functions such as protein assembly in the presynaptic active
472 zone. Supporting the potential role of liprin- β 1 in synapse formation and neurodevelopment,
473 we have shown here that a *C. elegans PPFIBP1/hlb-1* knockout model shows defects in
474 spontaneous and light-induced behaviour. The observed sensitivity of the worm model to the
475 acetylcholinesterase inhibitor aldicarb supports a presynaptic defect as at least a partial cause
476 of the observed behavioural phenotypes. This is broadly consistent with previous work
477 showing that null-allele mutants of the drosophila orthologues liprin- β and liprin- α
478 independently cause abnormal axon outgrowth, target layer recognition and synapse
479 formation of R7 photoreceptors as well as reduced larval NMJ size in *Drosophila*
480 *melanogaster*. Interestingly, distinct effects on axon outgrowth between single liprin- β and
481 liprin- α mutants and an additive effect in double mutants were observed, indicating
482 independent functions of both proteins.⁷

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

483 In summary, we establish bi-allelic loss-of-function variants in *PPFIBP1* as a novel cause for
484 an autosomal recessive neurodevelopmental disorder with early-onset epilepsy, microcephaly
485 and periventricular calcifications.

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

486 **Data and code availability**

487 The code used for tracking and extracting *C. elegans* behavioural features is available at
488 <https://github.com/Tierpsy> and code for performing statistical analysis and generating figures
489 is available at <https://github.com/Tom-OBrien/Phenotyping-hlb1-disease-model-mutant>. The
490 associated *C. elegans* datasets are available at <https://doi.org/10.5281/zenodo.6338403>.

491 The Morbid Genes Panel is available here <https://morbidgenes.org/> and here
492 <https://zenodo.org/record/6136995#.YiYvI-jMKUk>

493 Protocols used in this study are available here:

494 Barlow, Ida. Bleach Synchronisation of *C. Elegans* V1.

495 <https://doi.org/10.17504/protocols.io.2bzgap6>.

496 Barlow, Ida. Disease Model Screen Protocol V1.

497 <https://doi.org/10.17504/protocols.io.bsicncaw>.

498 Islam, Priota. Preparing Worms for the COPAS (Wormsorter) V1.

499 <https://doi.org/10.17504/protocols.io.bfqbjmsn>.

500 J O'Brien, Thomas. Pharyngeal Pumping Assay V1.

501 <https://doi.org/10.17504/protocols.io.b3hiqj4e>.

502 J. O'Brien, Thomas. Response of Disease Model Mutants to Cholinergic Drugs V1.

503 <https://doi.org/10.17504/protocols.io.b5p7q5m>.

504 Moore, Saul, and Ida Barlow. COPAS Wormsorter V1.

505 <https://doi.org/10.17504/protocols.io.bfc9jiz6>.

506 Barlow, Ida. Disease Model Screen Protocol V1.

507 <https://doi.org/10.17504/protocols.io.bsicncaw>.

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

508 **Supplemental information**

509 Supplemental data includes detailed case reports of the described individuals, three tables
510 (Table S1, Table S2, Table S3) and supplemental methods. Table S4 is provided separately as
511 an excel file.

512

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

513 **Acknowledgements**

514 We thank all families that participated in this study. This project has received funding from
515 the European Research Council (ERC) under the European Union’s Horizon 2020 Research
516 and Innovation Program (Grant Agreement No. 714853) and was supported by the Medical
517 Research Council through Grant MC-A658-5TY30. HT was supported by the European
518 Union’s Seventh Framework Programme for research, technological development and
519 demonstration under grant agreement no. 608473.

520

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

521 **Declaration of interests**

522 The authors declare no competing interests.

523

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

524 **Web resources**

525 GenBank, <https://www.ncbi.nlm.nih.gov/genbank/>

526 OMIM, <https://www.omim.org/>

527 GeneMatcher, <https://genematcher.org/>

528 MorbidGenes, <https://morbidgenes.org/>

529 gnomAD, <https://gnomad.broadinstitute.org/>

530 GTEx, <https://gtexportal.org/home/>

531 Ensembl, <https://www.ensembl.org/index.html>

532 PDB, <https://www.rcsb.org/>

533 SwissModel, <https://swissmodel.expasy.org/>

534

535 **References**

- 536 1. Serra-Pagès, C., Medley, Q.G., Tang, M., Hart, A., and Streuli, M. (1998). Liprins, a Family of
537 LAR Transmembrane Protein-tyrosine Phosphatase-interacting Proteins. *Journal of Biological*
538 *Chemistry* 273, 15611–15620.
- 539 2. Zürner, M., and Schoch, S. (2009). The mouse and human Liprin- α family of scaffolding proteins:
540 Genomic organization, expression profiling and regulation by alternative splicing. *Genomics* 93, 243–
541 253.
- 542 3. Wei, Z., Zheng, S., Spangler, S.A., Yu, C., Hoogenraad, C.C., and Zhang, M. (2011). Liprin-
543 Mediated Large Signaling Complex Organization Revealed by the Liprin- α /CASK and Liprin-
544 α /Liprin- β Complex Structures. *Molecular Cell* 43, 586–598.
- 545 4. Xie, X., Luo, L., Liang, M., Zhang, W., Zhang, T., Yu, C., and Wei, Z. (2020). Structural basis of
546 liprin- α -promoted LAR-RPTP clustering for modulation of phosphatase activity. *Nat Commun* 11,
547 169.
- 548 5. Spangler, S.A., and Hoogenraad, C.C. (2007). Liprin- α proteins: scaffold molecules for synapse
549 maturation. *Biochemical Society Transactions* 35, 1278–1282.
- 550 6. Xie, X., Liang, M., Yu, C., and Wei, Z. (2021). Liprin- α -Mediated Assemblies and Their Roles in
551 Synapse Formation. *Front. Cell Dev. Biol.* 9, 653381.
- 552 7. Astigarraga, S., Hofmeyer, K., Farajian, R., and Treisman, J.E. (2010). Three *Drosophila* Liprins
553 Interact to Control Synapse Formation. *Journal of Neuroscience* 30, 15358–15368.
- 554 8. Becker, M., Mastropasqua, F., Reising, J.P., Maier, S., Ho, M.-L., Rabkina, I., Li, D., Neufeld, J.,
555 Ballenberger, L., Myers, L., et al. (2020). Presynaptic dysfunction in CASK-related
556 neurodevelopmental disorders. *Transl Psychiatry* 10, 312.
- 557 9. Hsueh, Y.-P. (2009). Calcium/calmodulin-dependent serine protein kinase and mental retardation.
558 *Ann Neurol*. 66, 438–443.
- 559 10. Wang, D.-Y., and Wang, Y. (2009). HLB-1 functions as a new regulator for the organization and
560 function of neuromuscular junctions in nematode *Caenorhabditis elegans*. *Neurosci. Bull.* 25, 75–86.
- 561 11. Sobreira, N., Schiettecatte, F., Valle, D., and Hamosh, A. (2015). GeneMatcher: a matching tool
562 for connecting investigators with an interest in the same gene. *Hum Mutat* 36, 928–930.
- 563 12. Shaheen, R., Maddirevula, S., Ewida, N., Alsahli, S., Abdel-Salam, G.M.H., Zaki, M.S., Tala,
564 S.A., Alhashem, A., Softah, A., Al-Owain, M., et al. (2019). Genomic and phenotypic delineation of
565 congenital microcephaly. *Genetics in Medicine* 21, 545–552.
- 566 13. Jauss, Robin-Tobias, Popp, Bernt, Platzer, Konrad, and Jamra, Rami (2022). MorbidGenes-Panel-
567 v2022-02.1 (Zenodo).
- 568 14. Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alföldi, J., Wang, Q., Collins, R.L.,
569 Laricchia, K.M., Ganna, A., Birnbaum, D.P., et al. (2020). The mutational constraint spectrum
570 quantified from variation in 141,456 humans. *Nature* 581, 434–443.
- 571 15. Lonsdale, J., Thomas, J., Salvatore, M., Phillips, R., Lo, E., Shad, S., Hasz, R., Walters, G.,
572 Garcia, F., Young, N., et al. (2013). The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 45,
573 580–585.

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

- 574 16. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde, M.,
575 Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the interpretation of sequence
576 variants: a joint consensus recommendation of the American College of Medical Genetics and
577 Genomics and the Association for Molecular Pathology. *Genetics in Medicine* *17*, 405–424.
- 578 17. Guex, N., and Peitsch, M.C. (1997). SWISS-MODEL and the Swiss-PdbViewer: an environment
579 for comparative protein modeling. *Electrophoresis* *18*, 2714–2723.
- 580 18. Sayle, R.A., and Milner-White, E.J. (1995). RASMOL: biomolecular graphics for all. *Trends*
581 *Biochem Sci* *20*, 374.
- 582 19. Stiernagle, T. (2006). Maintenance of *C. elegans*. *WormBook*.
- 583 20. Barlow, I. Bleach synchronisation of *C. elegans* v1.
- 584 21. Islam, P. Preparing worms for the COPAS (wormsorter) v1.
- 585 22. Moore, S., and Barlow, I. COPAS wormsorter v1.
- 586 23. Disease model screen protocol v1.
- 587 24. J. O'Brien, T. (2022). Response of Disease Model Mutants to Cholinergic Drugs v1.
- 588 25. Barlow, I., Feriani, L., Minga, E., McDermott-Rouse, A., O'Brien, T., Liu, Z., Hofbauer, M.,
589 Stowers, J.R., Andersen, E.C., Ding, S.S., et al. (2021). Megapixel camera arrays for high-resolution
590 animal tracking in multiwell plates (*Animal Behavior and Cognition*).
- 591 26. Javer, A., Ripoll-Sánchez, L., and Brown, A.E.X. (2018). Powerful and interpretable behavioural
592 features for quantitative phenotyping of *Caenorhabditis elegans*. *Phil. Trans. R. Soc. B* *373*,
593 20170375.
- 594 27. Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and
595 Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series B*
596 (Methodological) *57*, 289–300.
- 597 28. J O'Brien, T. (2022). Pharyngeal Pumping Assay v1.
- 598 29. Lewis, B.P., Green, R.E., and Brenner, S.E. (2003). Evidence for the widespread coupling of
599 alternative splicing and nonsense-mediated mRNA decay in humans. *Proceedings of the National*
600 *Academy of Sciences* *100*, 189–192.
- 601 30. Anna, A., and Monika, G. (2018). Splicing mutations in human genetic disorders: examples,
602 detection, and confirmation. *J Appl Genetics* *59*, 253–268.
- 603 31. Baralle, D. (2005). Splicing in action: assessing disease causing sequence changes. *Journal of*
604 *Medical Genetics* *42*, 737–748.
- 605 32. Williams, S.N., Locke, C.J., Braden, A.L., Caldwell, K.A., and Caldwell, G.A. (2004). Epileptic-
606 like convulsions associated with LIS-1 in the cytoskeletal control of neurotransmitter signaling in
607 *Caenorhabditis elegans*. *Human Molecular Genetics* *13*, 2043–2059.
- 608 33. Miller, K.G., Alfonso, A., Nguyen, M., Crowell, J.A., Johnson, C.D., and Rand, J.B. (1996). A
609 genetic selection for *Caenorhabditis elegans* synaptic transmission mutants. *Proceedings of the*
610 *National Academy of Sciences* *93*, 12593–12598.

- 611 34. Waggoner, L.E., Dickinson, K.A., Poole, D.S., Tabuse, Y., Miwa, J., and Schafer, W.R. (2000).
612 Long-Term Nicotine Adaptation in *Caenorhabditis elegans* Involves PKC-Dependent Changes in
613 Nicotinic Receptor Abundance. *J. Neurosci.* *20*, 8802–8811.
- 614 35. Schultz, J., Bork, P., Ponting, C.P., and Hofmann, K. (1997). SAM as a protein interaction domain
615 involved in developmental regulation: Emergence of SAM. *Protein Science* *6*, 249–253.
- 616 36. Gonçalves, F.G., Caschera, L., Teixeira, S.R., Viaene, A.N., Pinelli, L., Mankad, K., Alves,
617 C.A.P.F., Ortiz-Gonzalez, X.R., Andronikou, S., and Vossough, A. (2020). Intracranial calcifications
618 in childhood: Part 1. *Pediatr Radiol* *50*, 1424–1447.
- 619 37. Livingston, J.H., Stivaros, S., Warren, D., and Crow, Y.J. (2014). Intracranial calcification in
620 childhood: a review of aetiologies and recognizable phenotypes. *Dev Med Child Neurol* *56*, 612–626.
- 621 38. Duncan, C.J.A., Thompson, B.J., Chen, R., Rice, G.I., Gothe, F., Young, D.F., Lovell, S.C.,
622 Shuttleworth, V.G., Brocklebank, V., Corner, B., et al. (2019). Severe type I interferonopathy and
623 unrestrained interferon signaling due to a homozygous germline mutation in *STAT2*. *Sci. Immunol.* *4*,
624 eaav7501.
- 625 39. Meuwissen, M.E.C., Schot, R., Buta, S., Oudesluijs, G., Tinschert, S., Speer, S.D., Li, Z., van
626 Unen, L., Heijman, D., Goldmann, T., et al. (2016). Human USP18 deficiency underlies type 1
627 interferonopathy leading to severe pseudo-TORCH syndrome. *Journal of Experimental Medicine* *213*,
628 1163–1174.
- 629 40. O’Driscoll, M.C., Daly, S.B., Urquhart, J.E., Black, G.C.M., Pilz, D.T., Brockmann, K.,
630 McEntagart, M., Abdel-Salam, G., Zaki, M., Wolf, N.I., et al. (2010). Recessive Mutations in the Gene
631 Encoding the Tight Junction Protein Occludin Cause Band-like Calcification with Simplified Gyration
632 and Polymicrogyria. *The American Journal of Human Genetics* *87*, 354–364.
- 633 41. Cerebral Calcification International Study Group, Tonduti, D., Panteghini, C., Pichiecchio, A.,
634 Decio, A., Carecchio, M., Reale, C., Moroni, I., Nardocci, N., Campistol, J., et al. (2018).
635 Encephalopathies with intracranial calcification in children: clinical and genetic characterization.
636 *Orphanet J Rare Dis* *13*, 135.
- 637 42. Wong, M.Y., Liu, C., Wang, S.S.H., Roquas, A.C.F., Fowler, S.C., and Kaeser, P.S. (2018).
638 Liprin- α 3 controls vesicle docking and exocytosis at the active zone of hippocampal synapses. *Proc*
639 *Natl Acad Sci USA* *115*, 2234–2239.
- 640 43. Kittelmann, M., Hegermann, J., Goncharov, A., Taru, H., Ellisman, M.H., Richmond, J.E., Jin, Y.,
641 and Eimer, S. (2013). Liprin- α /SYD-2 determines the size of dense projections in presynaptic active
642 zones in *C. elegans*. *Journal of Cell Biology* *203*, 849–863.
- 643 44. Patel, M.R., Lehrman, E.K., Poon, V.Y., Crump, J.G., Zhen, M., Bargmann, C.I., and Shen, K.
644 (2006). Hierarchical assembly of presynaptic components in defined *C. elegans* synapses. *Nat*
645 *Neurosci* *9*, 1488–1498.
- 646 45. Spangler, S.A., Schmitz, S.K., Kevenaer, J.T., de Graaff, E., de Wit, H., Demmers, J., Toonen,
647 R.F., and Hoogenraad, C.C. (2013). Liprin- α 2 promotes the presynaptic recruitment and turnover of
648 RIM1/CASK to facilitate synaptic transmission. *Journal of Cell Biology* *201*, 915–928.
- 649 46. de Curtis, I. (2011). Function of liprins in cell motility. *Experimental Cell Research* *317*, 1–8.
- 650 47. Chiaretti, S., and de Curtis, I. (2016). Role of Liprins in the Regulation of Tumor Cell Motility and
651 Invasion. *CCDT* *16*, 238–248.

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

652 48. Moog, U., and Kutsche, K. (1993). CASK Disorders. In GeneReviews®, M.P. Adam, H.H.
653 Ardinger, R.A. Pagon, S.E. Wallace, L.J. Bean, K.W. Gripp, G.M. Mirzaa, and A. Amemiya, eds.
654 (Seattle (WA): University of Washington, Seattle), p.

655

656

657 **Figure titles and legends**

658 **Figure 1. Prevalence of clinical findings, neuroimaging features and X-ray of the fetus.**

659 (A) Prevalence of phenotypic features in the cohort grouped by clinical categories (B) Fetus,
660 (removed due to medRxivpolicy), X-ray babygram postmortem: macroscopic intracranial
661 calcifications (arrows) (C) Exemplary MRI and CT images of, each column shows images of
662 one individual as indicated at the top. Ind. 2: a) MRI, age (removed due to medRxivpolicy),
663 T2-FLAIR transverse: pronounced leukoencephalopathy, paucity of the white matter,
664 consecutive ventriculomegaly b) CT, age (removed due to medRxivpolicy): bilateral
665 symmetrical calcifications periventricular and in the basal ganglia (arrows) ; Ind. 3-3: a) MRI,
666 age (removed due to medRxivpolicy), T2-TSE coronal: moderate ventriculomegaly with
667 accentuation of the occipital horn and pachygyria with thickening of the occipitotemporal
668 cortex (arrow) b) CT, (removed due to medRxivpolicy), bilateral calcifications periventricular
669 and in the deep white matter (arrows); Ind. 4: a) MRI, age (removed due to medRxivpolicy),
670 T2-TSE coronal: severe paucity of the white matter and consecutive ventriculomegaly,
671 bilateral pachygyria and thickening of the parietal cortex (arrows) b) CT, age (removed due to
672 medRxivpolicy): bilateral symmetrical calcifications periventricular and in the basal ganglia
673 (arrows); Ind 8: MRI, age (removed due to medRxivpolicy), T2-TSE coronal:
674 ventriculomegaly, pachygyria with thickening of the cortex (asterisk) and periventricular
675 grey matter heterotopia (arrow).

676 **Figure 2. Variant locations on protein level and structure of liprin-β1 illustrating the**
677 **effect of the p.(Gly726Val) exchange. (A)** Location of the variants on protein level aligned
678 to the liprin-β1 isoform 1 (GenBank: NP_003613.4 [GenBank: NM_003622.4]). and count of
679 each variant in the cohort. Truncating and splice-site variants are indicated by red dots, the
680 missense variant is indicating by an orange dot. Abbreviation: SAM, sterile alpha motif. (B)
681 Structure of the sterile alpha motif (SAM) domains in the wildtype protein. Gly726 is located

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

682 in a tight turn and makes interactions with Asn803 of the adjacent SAM-domain. Asn803 is
683 shown in grey and Gly726 is colored by atom type; the topology of the protein backbone is
684 schematically depicted with helices in red. **(C)** In the Gly726Val variant, a severe steric
685 overlap (yellow circle) between the sidechains of Val726 and Asn803 is observed, which will
686 disrupt the domain interface thereby altering the topology of the SAM-domain region.

687 **Figure 3. Behavioural phenotype of *Caenorhabditis elegans* *PPFIBP1* homolog, *hlb-***
688 ***I(syb4896)*. (A-C)** Example behavioural and postural features altered in the loss-of-function
689 *hlb-I(syb4896)* [*C. elegans* ortholog of *PPFIBP1*] mutant strain under baseline (pre-stimulus)
690 imaging conditions. Individual points marked on the box plots are average values from
691 multiple worms in a single well. The different point colours indicate data from independent
692 experimental days. The selected features were compared to the N2 reference strain using
693 block permutation t-tests and *p*-values are shown above the respective plots. **(D)** Pharyngeal
694 pumps per minute of *hlb-I(syb4896)* and N2 reference strain. **(E)** Overall fraction of worms
695 moving forwards 60 seconds prior and 80 seconds following stimulation with a 10 second
696 blue light pulse (blue shading). Coloured lines represent averages of the detected fraction of
697 paused worms across all biological replicates and shaded areas represent the 95% confidence
698 intervals. **(F-G)** Average changes in the total fraction of worms moving forward or paused
699 prior to, during and following stimulation with blue light, **(H)** average change in an example
700 postural feature in response to blue light. Feature values were calculated as averages of 10
701 second window summaries centred around 5 seconds before, 10 seconds after and 20 seconds
702 after the beginning of a 10 second blue light pulse (blue shading). **(I)** Heatmap of the entire
703 set of 8289 behavioural features extracted by Tierpsy for *hlb-I(syb4896)* and N2. The
704 stim_type barcode denotes when during image acquisition the feature was extracted: pre-
705 stimulation (pink), blue light stimulation (blue) and post-stimulation (green). Asterisks

Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

706 indicate the selected features present in the box plots above (A-C) and the colour map (right)
707 represents the normalised z-score of the features.

708

709 **Figure 4 Fraction of paused worms in response to treatment with aldicarb or levamisole.**

710 Overall fraction of paused worms after (A) 1h exposure to aldicarb and (B) 4h exposure to
711 levamisole at the concentrations denoted under the boxplots. N2 (grey) and *h1b-1* (blue) are
712 solvent only controls (DMSO and ddH₂O for aldicarb and levamisole, respectively).
713 Individual points marked on the box plots are averaged values from multiple worms in a
714 single well. The different point colours indicate data from independent experimental days.
715 The fraction of paused *h1b-1(syb4896)* worms was compared to the fraction of paused N2
716 worms at each concentration using block permutation t-tests, with $p > 0.05$ considered not
717 significant (ns), $n = 30$ wells for each compound and concentration tested.

718

Table 1. Phenotypic and Genetic Features of Individuals with bi-allelic variants in PPFIBP1

Ind.	Age ^a (Sex)	Variant (NM_003622.4)	Development	Seizure types (age of onset)	MRI (age)	ICC ^b	Neurological findings	Microce- phaly	Growth	CHD	Hearing	Ocular features
Ind. 1	(removed due to medRxiv policy) (M)	c.1146+1G>A, p?, homozygous	moderate ID, delayed speech, normal motor development	focal impaired awareness (removed due to medRxiv policy)	normal (removed due to medRxiv policy)	not done	none	yes	SGA	no	normal	normal
Ind. 2	(removed due to medRxiv policy) (F)	c.2654del, p.(Tyr885Leufs* 4), homozygous	profound DD, no speech, unable to sit	focal, generalized tonic clonic (removed due to medRxiv policy)	paucity of the WM, ventriculomegaly, hypoplastic CC, Blakes's pouch cyst (removed due to medRxiv policy)	yes	spastic tetraplegia, nystagmus	yes	short stature, low weight	no	left hypo- acusis	bilateral papillary pallor, no eye contact
Ind. 3-1	(removed due to medRxiv policy) (M)	c.1368_1369del, p.(Glu456Aspfs* 3), homozygous	profound DD, no speech, unable to sit	epileptic spasms, focal, tonic clonic, tonic (removed due to medRxiv policy)	periventricular leukomalacia, metopic synostosis	yes	spastic tetraplegia	yes	SGA, low weight	yes	impaired	poor fixation
Ind. 3-2	(removed due to medRxiv policy) (M)	c.1368_1369del, p.(Glu456Aspfs* 3), homozygous	profound DD, no speech, unable to sit	epileptic spasms, LGS (removed due to medRxiv policy)	moderate hyperintensity of periventricular white matter, mild ventriculomegaly (removed due to medRxiv policy)	yes	spastic tetraplegia	yes	SGA, low weight	yes	impaired	normal
Ind. 3-3	(removed due to medRxiv policy) (M)	c.1368_1369del, p.(Glu456Aspfs* 3), homozygous	profound DD, no speech, unable to sit	epileptic spasms, focal, multifocal (removed due to medRxiv policy)	ventriculomegaly, abnormal signal intensity of the WM, bilateral temporal and left occipital pachygyria (removed due to medRxiv policy)	yes	spastic tetraplegia	yes	SGA, low weight	yes	impaired	normal
Ind. 4	(removed due to medRxiv policy) (M)	c.1368_1369del, p.(Glu456Aspfs* 3), homozygous	profound DD no speech, unable to sit	epileptic spasms, focal, generalized tonic, status epilepticus (removed due to medRxiv policy)	ventriculomegaly, paucity of the WM, bilateral parietal and occipital pachygyria (removed due to medRxiv policy)	yes	spastic diplegia, hyperreflexia	yes	SGA, short stature	yes	not tested	haemorrhagic retinitis, chronic retinal detachment, right eye exotropia w/ slow pupillary reaction
Ind. 5-1	(removed due to medRxiv policy) (F)	c.2413C>T, p.(Arg805*), homozygous	profound DD, no speech, unable to sit	focal, myoclonic (removed due to medRxiv policy)	not done	yes	spastic tetraplegia	yes	SGA, short stature, low weight	no	normal	NA

Table 1. Phenotypic and Genetic Features of Individuals with bi-allelic variants in PPFIBP1

Ind.	Age ^a (Sex)	Variant (NM_003622.4)	Development	Seizure types (age of onset)	MRI (age)	ICC ^b	Neurological findings	Microce phaly	Growth	CHD	Hearing	Ocular features
Ind. 5-2	removed due to medRxiv policy (F)	c.2413C>T, p.(Arg805*), homozygous	profound DD, no speech, unable to sit	focal, myoclonic, tonic (removed due to medRxiv policy)	not done, ventriculomegaly on CT	yes	hypertonia of the limbs, dystonia	yes	short stature	no	normal	normal
Ind. 6-1	removed due to medRxiv policy (M)	c.1468C>T, p.(Gln490*), homozygous	profound DD, no speech, sat independently at 6y	generalized tonic clonic, myoclonic (removed due to medRxiv policy)	ventriculomegaly, cortical atrophy, demyelination of periventricular WM, thin CC, cerebellar vermian hypoplasia	not done	hypertonia of the limbs	yes	short stature, low weight	no	normal	optic atrophy, followed light
Ind. 6-2	removed due to medRxiv policy (M)	c.1468C>T, p.(Gln490*), homozygous	profound DD, no speech, no head support	generalized tonic clonic, myoclonic, excessive smacking movements (removed due to medRxiv policy)	asymmetrical ventriculomegaly, cortical atrophy, demyelination of periventricular WM, thin CC, cerebellar vermian hypoplasia	yes	spasticity, rigidity, dystonic movement	yes	short stature, low weight	yes	normal	optic atrophy, couldn't follow light
Ind. 7	removed due to medRxiv policy (F)	c.403C>T, p.(Arg135*), homozygous	severe DD, no speech, motor delay but can stand and walk	epileptic spasms, focal with apnoea, myoclonic (removed due to medRxiv policy)	normal at (removed due to medRxiv policy); thin CC, periventricular dysmyelination, possibly reduction of the WM at (removed due to medRxiv policy)	not done	hypotonia	yes	normal	no	normal	normal
Ind. 8	removed due to medRxiv policy (F)	c.1417_1427del, p.(Ala473Lysfs* 20), homozygous	profound DD, no speech, unable to sit	generalized tonic clonic (removed due to medRxiv policy)	bilateral parietal pachygyria, periventricular heterotopia, ventriculomegaly, hyperintensity and paucity of the WM	NA	hypotonia, nystagmus	no, but low OFC	SGA	yes	normal	normal, but poor fixation
Ind. 9	removed due to medRxiv policy (M)	c.1300C>T, p.(Gln434*), homozygous	severe DD, no speech, can sit but not walk	epileptic spasms and gaze (removed due to medRxiv policy)	abnormal	NA	spastic tetraplegia, no sphincter control	yes	SGA	no	normal	blindness



Table 1. Phenotypic and Genetic Features of Individuals with bi-allelic variants in PPFIBP1

Ind.	Age ^a (Sex)	Variant (NM_003622.4)	Development	Seizure types (age of onset)	MRI (age)	ICC ^b	Neurological findings	Microce phaly	Growth	CHD	Hearing	Ocular features
Ind. 10	removed due to medRxiv policy (M)	c.2629C>T, p.(Arg877*), homozygous	severe DD, no speech yet, motor delay	focal myoclonic, epileptic spasms (removed due to medRxiv policy)	abnormal myelination of the periventricular WM and at corona radiata and centrum semiovale, hypoplastic CC, mild ventriculomegaly	NA	hypotonia, nystagmus	yes	NA	no	normal	right ptosis, left iris coloboma, diffuse chorioretinal degeneration
Fetus (Ind. 11)	removed due to medRxiv policy	c.2177G>T, p.(Gly726Val), homozygous	developmental age estimated around (removed due to medRxiv policy)	-	-	Yes ^d	-	yes	IUGR	-	-	-


Abbreviations: CC, corpus callosum; CHD, congenital heart defects; d, days; DD, developmental delay; F, female; IUGR, intrauterine growth restriction; GDD, global developmental delay; GW, gestational week; ICC, intracranial calcifications; ID, intellectual disability; LGS, Lennox-Gastaut syndrome; M, male; m, months; NA, not available; OFC, occipitofrontal circumference; SGA, small for gestational age; w, weeks; WM, white matter; y, years. Further clinical details are provided in Table S4.




^a age at last assessment; ^b on CT scan; ^c deceased (age at death); ^d ICCs seen on x-ray babygram



Rosenhahn *et al.*, *PPFIBP1*-related neurodevelopmental disorder

(A)**(B)****(C)**

Individual 2 Individual 3-3 Individual 4 Individual 8



(A)**(B)****(C)**



(I) 1148/8289 significant features

